Risankizumab in Psoriasis: Real-World Effectiveness, Safety, and Clinical Outcomes
Background Risankizumab (anti–IL-23 p19) is an established therapy for moderate-to-severe psoriasis, with strong trial efficacy and growing real-world evidence. However, long-duration outcomes and treatment-spacing patterns from the Gulf region remain limited. Objective To evaluate long-term effectiveness, safety, and...